Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10187244 | 1.00 | DPP4 (0.36) | DPP4JAK3TSHRNFKB1CYP2C19 | |
| SCHEMBL16980483 | 0.81 | DPP4 (0.35) | DPP4TSHRNFKB1CYP2C19 | |
| SCHEMBL4743137 | 0.81 | DPP4 (0.35) | DPP4TSHRNFKB1CYP2C19 | |
| SCHEMBL16563021 | 0.81 | DPP4 (0.35) | DPP4TSHRNFKB1CYP2C19 | |
| SCHEMBL4742170 | 0.76 | CYP1A2 (0.41) | TSHRCYP2C19 | |
| SCHEMBL4742521 | 0.76 | POLB (0.38) | DPP4TSHRNFKB1CYP2C19 | |
| SCHEMBL4743121 | 0.76 | CYP1A2 (0.41) | DPP4JAK3TSHRCYP2C19 | |
| SCHEMBL4742512 | 0.76 | DPP4 (0.38) | DPP4JAK3TSHRNFKB1CYP2C19 | |
| SCHEMBL27010259 | 0.76 | TSHR (0.32) | DPP4TSHRNFKB1CYP2C19 | |
| SCHEMBL4731041 | 0.75 | DPP4 (0.35) | DPP4JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | THERAVANCE, INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, ZC3HAV1 | DPP4 475/4885JAK3 136/4885TSHR 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.